Biomarkers in Patients With Acute Myeloid Leukemia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01138319|
Recruitment Status : Completed
First Posted : June 7, 2010
Last Update Posted : May 6, 2015
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
PURPOSE: This research study is studying biomarkers in patients with acute myeloid leukemia.
|Condition or disease||Intervention/treatment|
|Leukemia||Genetic: DNA analysis Genetic: mutation analysis Genetic: polymerase chain reaction Other: laboratory biomarker analysis|
- To determine whether clonally expanded somatic mitochondrial DNA mutations are associated with acute myeloid leukemia.
OUTLINE: Genomic DNA from blood samples obtained at diagnosis, remission, and relapse are analyzed for mitochondrial DNA mutations via PCR.
|Study Type :||Observational|
|Actual Enrollment :||18 participants|
|Official Title:||Mitochondrial Mutations and AML|
|Study Start Date :||February 2009|
|Actual Primary Completion Date :||March 2010|
- Association between clonally expanded somatic mitochondrial DNA mutations and acute myeloid leukemia
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01138319
|Principal Investigator:||Jason H. Bielas, PhD||Fred Hutchinson Cancer Research Center|